The company raised its full-year revenue guidance to a range of $94 million to $98 million, up from the previous range of $93 million to $97 million, and updated ...
NeuroPace, Inc. NPCE is well-positioned for solid growth, driven by strong RNS adoption, expanding referral networks and ...
NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic ...
MOUNTAIN VIEW, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today ...
4 analysts have shared their evaluations of NeuroPace (NASDAQ:NPCE) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results